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Background: Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case–control study reported
serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been
investigated prospectively.
Methods: We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358
individually matched controls from three cohorts participating in the MM cohort consortium.
Results: In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a
statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24–0.83
and 0.54; 95% CI 0.29–0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; Ptrend¼ 0.03). No association was
observed for women.
Conclusions: This study provides the first prospective evidence that low circulating resistin levels may be associated with an
increased risk of MM, particularly for men.
Multiple myeloma (MM), a plasma cell disease, was newly
diagnosed in an estimated 24 280 individuals in 2016
in the United States (Teras et al, 2016). Besides well-established
risk factors, such as male sex, older age, African ancestry, and a
family history of haematological malignancies (Baris et al, 2013),
obesity has been shown to increase MM risk (Teras et al, 2014).
The association between obesity and MM may be attributable in
part to altered levels of various adipokines (e.g., adiponectin,
leptin, and resistin) secreted by adipose tissue (Dalamaga et al,
2009). We have recently shown that the risk of MM is increased for
individuals with low pre-diagnosis circulating levels of adiponectin
(Hofmann et al, 2016), but not of leptin (Hofmann et al, 2012).
The potential role of resistin in MM development is poorly
understood. An increased risk of MM for individuals with
low serum levels of resistin was observed by one small hospital-
based case–control study (73 MM cases and 73 controls)
(Dalamaga et al, 2009). To our knowledge, the relationship
between resistin and MM has not been evaluated prospectively.
Using a nested case–control study involving three cohorts
participating in the MM cohort consortium, we investigated
whether pre-diagnosis circulating levels of resistin were associated
with future MM risk.
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MATERIALS AND METHODS
Cases (n¼ 178) and controls (n¼ 358) were selected from the
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study
(ATBC), the Cancer Prevention Study II (CPS-II), and the
Melbourne Collaborative Cohort Study (MCCS) (ATBC, 1994;
Calle et al, 2002; Giles and English, 2002). Participating cohorts
received Institutional Review Board approval from their respective
institutions. We selected cases with a primary incident diagnosis of
MM (ICDA¼ 203; ICD-O-2-M¼ 9731, 9732, and 9830; or ICD-
O-3-M¼ 9731–9734) and a stored blood sample collected X3
months before MM diagnosis. Controls with no history of cancer
were individually matched to cases based on cohort of origin, birth
year (±12 months), sex, type of blood sample (serum, plasma-
heparin, and plasma-EDTA), date of blood collection (±2
months), and fasting status at blood draw with a 2 : 1 ratio as
previously described (Birmann et al, 2012; Hofmann et al, 2016).
All of the cases and controls included in this investigation were
non-Hispanic whites.
Circulating levels of resistin were measured in duplicate by ELISA
(Human Resistin Quantikine ELISA by R&D Systems, Inc.,
Minneapolis, MN, USA). Assays were performed in the laboratory
of MNP at McGill University. The lower limit of detection was
0.156 ngml 1. Samples from MM patients and their matched
controls were analysed in the same batch, and blinded quality control
(QC) replicates were included in each batch as previously described
(Hofmann et al, 2016). The overall intraclass correlation coefficient
was 0.86, and the coefficient of variation for pooled QC specimens
was 6.1%, with no evidence of laboratory drift across cohorts.
We used the Wilcoxon rank-sum test to assess differences in
resistin levels between cases and controls. For our main analyses, we
performed cohort- and sex-specific corrections of resistin values to
reduce the impact of cohort-related variability, and to account for
differences between men and women within and across the
participating studies (Birmann et al, 2012; Hofmann et al, 2016)
(Supplementary Methods). Odds ratios (ORs) and 95% confidence
intervals (95% CIs) for risk of MM were computed using conditional
logistic regression models with levels of resistin categorised into
quartiles based on the distribution among controls. We performed
analyses stratified by sex, time to MM diagnosis, and age at sample
collection using conditional logistic regression models, and analyses
stratified by BMI categories using unconditional logistic regression
models adjusted for matching factors. Multiplicative interaction was
assessed using Wald tests. Study-specific ORs and 95% CIs were
estimated comparing resistin levels above and below the median
(based on the distribution in controls); we conducted a meta-
analysis using both fixed and random effects models, and assessed
heterogeneity across cohorts using the Cochran Q-test and the I2
statistic. For all analyses, findings were considered statistically
significant if the two-sided P-value was o0.05.
RESULTS
Cases and controls had similar distributions of sex, age at the blood
draw, and type of blood sample (Table 1). Cohort- and sex-
corrected resistin levels were somewhat lower among cases
compared with controls; these differences were statistically
significant among men (P¼ 0.006, Wilcoxon rank-sum test) but
not among women (P¼ 0.22). Levels of resistin and total
adiponectin (measured previously) were not correlated among
cases or controls (Spearman’s correlation coefficients of  0.07
and 0.09, respectively; PX0.1). In multivariate analyses of the
pooled controls, circulating levels of resistin were higher among
men compared with women, but were not associated with age or
BMI (Supplementary Table S1).
Higher resistin levels were weakly associated with a reduced risk
of MM in overall analyses, although the observed associations were
not statistically significant (Table 2). Findings were similar after
adjusting for BMI and adiponectin levels. Among a subset of
participants from the ATBC and MCCS cohorts with available data
on markers related to IGF-1 and interleukin (IL)-6 pathways
(Birmann et al, 2012), we found that results were essentially
unchanged after adjustment for these other analytes (data not
shown). Among men, we observed a statistically significant
reduced risk of MM among those with higher levels of resistin
(ORs of 0.44 (95% CI 0.24–0.83) and 0.54 (0.29–0.99) for the third
and fourth quartiles, respectively, vs the lowest quartile;
Ptrend¼ 0.026). This association remained after adjusting for BMI
and adiponectin levels (data not shown). In contrast, resistin
levels were not associated with MM risk among women
(Pinteraction¼ 0.12). In other stratified analyses, we did not observe
statistically significant differences in the ORs across strata for time
to MM diagnosis, BMI category, or age at blood collection. Our
main findings were essentially unchanged after excluding high
outlying resistin levels and when quartiles were based on the
overall distribution of resistin levels among controls rather than the
cohort- and sex-corrected levels.
Cohort- and sex-specific results are shown in Figure 1. Among
men, there was some evidence of heterogeneity across cohorts
(I2¼ 62.3%, P¼ 0.071). The association was strongest among men
in the MCCS (OR 0.12, 95% CI 0.026–0.53), although non-
significant inverse associations were also observed among men in
the other cohorts (ORs of 0.63 (0.30–1.34) and 0.79 (0.42–1.48) in
CPS-II and ATBC, respectively). Among women, ORs were
elevated but not statistically significant in both CPS-II and MCCS.
DISCUSSION
This study is, to our knowledge, the first prospective investigation
of circulating levels of resistin and risk of MM. Our findings
Table 1. Selected characteristics of cases and controls
Characteristic Casesa Controlsa
Patients 178 (100) 358 (100)
Cohort
ATBC 59 (33.2) 117 (32.7)
CPS-II 67 (37.6) 135 (37.7)
MCCS 52 (29.2) 106 (29.6)
Sex
Female 49 (27.5) 100 (27.9)
Male 129 (72.5) 258 (72.1)
Mean (s.d.) age at blood draw 63.0 (7.8) 63.0 (7.8)
Mean (s.d.) BMI at blood draw, kg/m2 26.9 (4.0) 26.5 (4.2)
Type of blood sample
EDTA 67 (37.6) 135 (37.7)
Heparin plasma 52 (29.2) 106 (29.6)
Serum 59 (33.2) 117 (32.7)
Time from blood draw to diagnosis
o7 years 85 (47.8)
X7 years 93 (52.3)
Median resistin concentrationb (IQR)
Overall 5.47 (4.08–7.11) 5.82 (4.47–7.37)
Female 6.24 (5.11–8.44) 5.88 (4.48–7.66)
Male 5.20 (3.93–6.46)c 5.82 (4.44–7.33)
Abbreviations: ATBC¼Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BMI¼
body mass index; CPS-II¼ the Cancer Prevention Study II; IQR¼ interquartile range;
MCCS¼Melbourne Collaborative Cohort Study.
aReported as N (%) unless otherwise noted.
bOn the basis of corrected resistin levels in ngml 1 (Supplementary Methods).
cWilcoxon two-sample test P¼ 0.006.
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suggest that high pre-diagnosis circulating resistin levels
are associated with a reduced future risk of MM development, in
particular among men. These results are consistent with
findings from a prior hospital-based case–control study
(Dalamaga et al, 2009). Although we did not find evidence of an
association among women, our investigation included relatively
few female MM cases and thus we had limited statistical power for
this subgroup analysis. Our findings may also reflect true
differences by sex in the biological activity of resistin due to
interaction with sex or metabolic hormones or other inflammatory
markers that are differentially expressed in men and women
(Dalamaga et al, 2013). We also observed a somewhat stronger
association during the time period closer to MM diagnosis, which
may reflect altered resistin expression related to onset or
progression of monoclonal gammopathy of undetermined
significance.
Resistin increases nuclear factor kappa B-related monocyte
expression of pro-inflammatory cytokines such as IL-6 (Tilg and
Moschen, 2006; Lee et al, 2014). Thus, the observed increased risk
of MM in males with lower levels of resistin might reflect a
compensatory effect of resistin or a negative feedback loop
following the production of IL-6 and/or other cytokines with
known effects on proliferation and survival of MM cells (Dalamaga
et al, 2009). Alternatively, previous studies have shown that TNF-a
Table 2. Circulating resistin levels and risk of MM, overall and stratified by selected characteristics
Quartile (Q)
Q1 Q2 Q3 Q4
Ncases OR (95% CI) Ncases OR (95% CI) Ncases OR (95% CI) Ncases OR (95% CI) Ptrend Pint
a
Crude 55 1.0 (ref) 48 0.87 (0.53–1.44) 33 0.61 (0.36–1.03) 42 0.75 (0.45–1.25) 0.20
Adjusted for BMI 54 1.0 (ref) 48 0.87 (0.52–1.46) 32 0.60 (0.35–1.02) 41 0.76 (0.45–1.29) 0.24
Adjusted for BMI and adiponectin 54 1.0 (ref) 48 0.86 (0.51–1.43) 32 0.59 (0.35–1.01) 41 0.76 (0.45–1.29) 0.24
By sex
Female 9 1.0 (ref) 11 1.27 (0.44–3.64) 12 1.56 (0.55–4.45) 17 1.82 (0.66–5.00) 0.23
Male 46 1.0 (ref) 37 0.77 (0.43–1.38) 21 0.44 (0.24–0.83) 25 0.54 (0.29–0.995) 0.03 0.12
By time to MM diagnosis
o7 years 28 1.0 (ref) 20 0.63 (0.29–1.37) 14 0.41 (0.18–0.90) 23 0.61 (0.30–1.25) 0.21
X7 years 27 1.0 (ref) 28 1.14 (0.58–2.26) 19 0.92 (0.45–1.87) 19 0.87 (0.41–1.86) 0.61 0.47
By BMI_categoryb
o25 kgm2 23 1.0 (ref) 12 0.59 (0.25–1.36) 13 0.68(0.29–1.57) 13 0.61 (0.27–1.40) 0.30
25–29.9 kgm2 19 1.0 (ref) 26 0.98 (0.44–2.18) 17 0.60 (0.26–1.42) 16 0.62 (0.26–1.52) 0.20
X30 kgm2 12 1.0 (ref) 10 1.31 (0.43–3.95) 2 0.23 (0.04–1.21) 12 1.47 (0.46–4.64) 0.91 0.45
By age at blood draw
o65 years 34 1.0 (ref) 31 0.86 (0.45–1.64) 17 0.55 (0.27–1.13) 18 0.61 (0.29–1.26) 0.12
X65 years 21 1.0 (ref) 17 0.87 (0.38–1.97) 16 0.64 (0.29–1.41) 24 0.89 (0.42–1.91) 0.78 0.76
Abbreviations: BMI¼body mass index; CI¼ confidence interval; MM¼multiple myeloma; OR¼odds ratio; Pint¼Pinteraction; ref¼ reference. Odds ratios and 95% CI were estimated using
conditional logistic regression models, unless otherwise noted. Quartile cut-off points were defined on the basis of the distribution of cohort- and sex-adjusted resistin levels among controls, as
follows: Q1p4.59 ngml 1, Q2 4.60–5.82 ngml 1, Q3 5.83–7.37 ngml 1, and Q4X7.38 ngml 1.
aTests of multiplicative interaction were based on the same models as those used for the stratified analyses and were performed using Wald tests.
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Figure 1. Cohort-specific and meta-analysis summary ORs and 95% CIs for the association between circulating resistin levels (above vs below
the median) and MM risk among men (upper panel) and women (lower panel).
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decreases resistin secretion in murine models (Rajala et al, 2002). If
TNF-a, a well-characterised pro-inflammatory cytokine that
stimulates MM cell proliferation (Hideshima et al, 2001), also acts
as a negative regulator of resistin in humans, this action may
explain the observed inverse association between pre-diagnosis
resistin levels and MM risk. This hypothesis is corroborated by
increased resistin levels in MM patients after treatment with
thalidomide, a TNF-a inhibitor (Reseland et al, 2009).
Resistin deregulation in obesity-related inflammatory conditions
may also result from altered expression by non-adipocyte
inflammatory cells, such as macrophages, in adipose tissue (Patel
et al, 2003; Curat et al, 2006). While some studies have observed
elevated levels of resistin among individuals with higher BMI or
visceral fat area (Yannakoulia et al, 2003; Reseland et al, 2009),
other studies found no association (Lee et al, 2003; Dalamaga et al,
2013). The lack of association of resistin with BMI in our study
suggests that resistin may influence MM risk through other
inflammatory processes. Notably, resistin is also highly expressed
in the bone marrow (BM) where it is secreted by osteoclasts and
osteoblasts, as well as by monocytes and macrophages (Patel et al,
2003). Resistin activates osteoclastogenesis and promotes osteo-
blast proliferation (Thommesen et al, 2006), which suggests a role
for resistin in bone remodelling. Considering the interplay between
the BM microenvironment and the proliferation of MM cells (Eda
et al, 2016), impaired resistin expression in the BM niche may
induce changes that are favourable to the proliferation of MM cells,
which might explain the observed inverse association between
resistin and MM risk. Functional analyses in BM tissue could help
to clarify the role of resistin and other adipokines in MM
pathogenesis.
The strengths of our study include its prospective design and the
pooling of data across three cohorts. Limitations include the lack of
detailed information on clinical characteristics of MM at diagnosis,
as well as information on family history of lymphohaematopoietic
malignancies. Given that having a family history of these relatively
rare malignancies is uncommon in the general population
(Schinasi et al, 2016), the potential for confounding by family
history is likely to be minimal. However, further investigation in
family-based studies and other studies with detailed clinical
records may be informative. Finally, although this study is the
largest to date that has evaluated the association between
resistin and MM, we had limited statistical power for analyses
restricted to women, as well as for the cohort-specific and
other stratified analyses. Extending this investigation to other
prospective cohorts is required to confirm our findings and to
better elucidate the differences by sex in the relationship between
resistin and MM.
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